Replies to post #3596 on CardioVascular BioTherapeutics (fka CVBT)

[walhall]

Why would Venturis Therapeutic's leadership want any of us to discuss the unchallengable fact that Dentons, the company's long-time counsel, quit in April and stated under penalty of perjury to a court that Venturis has no assets of value nor income streams from which to pay $200,000+ in overdue invoices?

This very uncomfortable fact (which can not be challenged) completely invalidates and negates the narrative that Venturis Therapeutic's leadership continues to try to spin. Namely, that Venturis Therapeutics remains viable.

So I completely understand why Venturis Therapeutics' leadership would want us all to move beyond discussing that fact.

For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157492465